Benefit of treatment of latent tuberculosis infection in individual patients

European Respiratory Journal

Volumn 46, Issue 5, 2015, Pages 1397-1406

  Dobler, Claudia C ^a,b   Martin, Andrew ^a   Marks, Guy B ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGED; AGING; ALLERGY; ARTICLE; CAUSE OF DEATH; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HEPATITIS; HUMAN; INFANT; INFECTION RISK; INTOXICATION; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POSTPRIMARY TUBERCULOSIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEX DIFFERENCE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; MARKOV CHAIN; MORTALITY; RECURRENT DISEASE; RISK; TOXIC HEPATITIS; TUBERCULIN TEST; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; CHILD; DRUG-INDUCED LIVER INJURY; FEMALE; HEPATITIS; HUMANS; ISONIAZID; LATENT TUBERCULOSIS; MALE; MARKOV CHAINS; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; RECURRENCE; RISK; TREATMENT OUTCOME; TUBERCULIN TEST; YOUNG ADULT;

EID: 84946599897     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00577-2015     Document Type: Article

References (33)

1. Lonnroth K, Migliori GB, Abubakar I, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J 2015; 45: 928-952.
2. Diel R, Loddenkemper R, Zellweger JP, et al. Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination. Eur Respir J 2013; 42: 785-801.
3. D'Ambrosio L, Dara M, Tadolini M, et al. Tuberculosis elimination: theory and practice in Europe. Eur Respir J 2014; 43: 1410-1420.
4. Horsburgh CR Jr, Goldberg S, Bethel J, et al. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest 2010; 137: 401-409.
5. Colson PW, Hirsch-Moverman Y, Bethel J, et al. Acceptance of treatment for latent tuberculosis infection: prospective cohort study in the United States and Canada. Int J Tuberc Lung Dis 2013; 17: 473-479.
6. Rose DN, Schechter CB, Silver AL. The age threshold for isoniazid chemoprophylaxis. A decision analysis for low-risk tuberculin reactors. JAMA 1986; 256: 2709-2713.
7. Colice GL. Decision analysis, public health policy, and isoniazid chemoprophylaxis for young adult tuberculin skin reactors. Arch Intern Med 1990; 150: 2517-2522.
8. Salpeter SR, Sanders GD, Salpeter EE, et al. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis. Ann Intern Med 1997; 127: 1051-1061.
9. Sarasin FP, Perrier A, Rochat T. Isoniazid preventive therapy for pulmonary tuberculosis sequelae: which patients up to which age? Tuber Lung Dis 1995; 76: 394-400.
10. Rose DN. Benefits of screening for latent Mycobacterium tuberculosis infection. Arch Intern Med 2000; 160: 1513-1521.
11. Sadatsafavi M, Marra C, Marra F, et al. A quantitative benefit-risk analysis of isoniazid for treatment of latent tuberculosis infection using incremental benefit framework. Value Health 2013; 16: 66-75.
12. Tsevat J, Taylor WC, Wong JB, et al. Isoniazid for the tuberculin reactor: take it or leave it. Am Rev Respir Dis 1988; 137: 215-220.
13. Jordan TJ, Lewit EM, Reichman LB. Isoniazid preventive therapy for tuberculosis. Decision analysis considering ethnicity and gender. Am Rev Respir Dis 1991; 144: 1357-1360.
14. Mack U, Migliori GB, Sester M, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 2009; 33: 956-973.
15. Menzies D, Gardiner G, Farhat M, et al. Thinking in three dimensions: a web-based algorithm to aid the interpretation of tuberculin skin test results. Int J Tuberc Lung Dis 2008; 12: 498-505.
16. Comstock GW, Edwards LB, Livesay VT. Tuberculosis morbidity in the U.S. Navy: its distribution and decline. Am Rev Respir Dis 1974; 110: 572-580.
17. Sterling TR, Brehm WT, Frieden TR. Isoniazid preventive therapy in areas of high isoniazid resistance. Arch Intern Med 1995; 155: 1622-1628.
18. Dobler CC, Marks GB. Risk of tuberculosis among contacts in a low-incidence setting. Eur Respir J 2013; 41: 1459-1461.
19. The Online TST/IGRA Interpreter, Version 3.0. McGill University and McGill University Health Center Montreal Quebec, Canada. http://www.tstin3d.com/en/calc.html. Date last accessed: April 12, 2015.
20. Walpola HC, Siskind V, Patel AM, et al. Tuberculosis-related deaths in Queensland, Australia, 1989-1998: characteristics and risk factors. Int J Tuberc Lung Dis 2003; 7: 742-750.
21. Smith BM, Schwartzman K, Bartlett G, et al. Adverse events associated with treatment of latent tuberculosis in the general population. CMAJ 2011; 183: E173-E179.
22. Millard PS, Wilcosky TC, Reade-Christopher SJ, et al. Isoniazid-related fatal hepatitis. West J Med 1996; 164: 486-491.
23. Smieja MJ, Marchetti CA, Cook DJ, et al. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2000; 2: CD001363.
24. Dion MJ, Tousignant P, Bourbeau J, et al. Feasibility and reliability of health-related quality of life measurements among tuberculosis patients. Qual Life Res 2004; 13: 653-665.
25. Dion M-J, Tousignant P, Bourbeau J, et al. Measurement of health preferences among patients with tuberculous infection and disease. Med Decis Making 2002; 22: Suppl. 5, S102-S114.
26. Awaisu A, Haniki Nik Mohamed M, Noordin NM, et al. Impact of connecting tuberculosis directly observed therapy short-course with smoking cessation on health-related quality of life. Tob Induc Dis 2012; 10: 2.
27. Centers for Disease Control and Prevention. United States Life Tables, 2009. NVSR Volume 62, Number 07.63 pp. (PHS) 2014-1120. http://www.cdc.gov/nchs/products/life-tables.htm. Date last updated: June 6, 2014. Date last accessed: April 12, 2015.
28. Straetemans M, Glaziou P, Bierrenbach AL, et al. Assessing tuberculosis case fatality ratio: a meta-analysis. PLoS One 2011; 6: e20755.
29. World Health Organization. Guidelines on the management of latent tuberculosis infection. Geneva, 2015. WHO reference number: WHO/HTM/TB/2015. 01.
30. Kahneman D. Thinking, Fast and Slow. New York, Farrar, Straus and Giroux, 2011.
31. Dobler CC, Crawford AB, Jelfs PJ, et al. Recurrence of tuberculosis in a low-incidence setting. Eur Respir J 2009; 33: 160-167.
32. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011; 365: 2155-2166.
33. Menzies D, Al Jahdali H, Al Otaibi B. Recent developments in treatment of latent tuberculosis infection. Indian J Med Res 2011; 133: 257-266.